A detailed history of Price T Rowe Associates Inc transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 4,944,757 shares of CRNX stock, worth $267 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
4,944,757
Previous 4,406,456 12.22%
Holding current value
$267 Million
Previous $197 Million 28.03%
% of portfolio
0.03%
Previous 0.02%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$43.83 - $54.98 $23.6 Million - $29.6 Million
538,301 Added 12.22%
4,944,757 $253 Million
Q2 2024

Aug 14, 2024

BUY
$42.12 - $51.91 $24.6 Million - $30.3 Million
583,238 Added 15.26%
4,406,456 $197 Million
Q1 2024

May 15, 2024

BUY
$34.76 - $46.81 $28.3 Million - $38.1 Million
814,360 Added 27.07%
3,823,218 $179 Million
Q4 2023

Feb 14, 2024

BUY
$25.62 - $37.07 $11 Million - $16 Million
430,659 Added 16.7%
3,008,858 $107 Million
Q3 2023

Nov 14, 2023

BUY
$15.97 - $30.59 $18.4 Million - $35.2 Million
1,149,289 Added 80.43%
2,578,199 $76.7 Million
Q2 2023

Aug 14, 2023

BUY
$15.73 - $23.6 $21.8 Million - $32.7 Million
1,387,127 Added 3319.84%
1,428,910 $25.8 Million
Q1 2023

May 15, 2023

SELL
$15.31 - $21.1 $155,365 - $214,122
-10,148 Reduced 19.54%
41,783 $672,000
Q4 2022

Feb 14, 2023

SELL
$15.49 - $19.05 $150,314 - $184,861
-9,704 Reduced 15.74%
51,931 $951,000
Q3 2022

Nov 14, 2022

BUY
$18.11 - $22.37 $130,899 - $161,690
7,228 Added 13.29%
61,635 $1.21 Million
Q2 2022

Aug 15, 2022

BUY
$16.49 - $27.64 $277,427 - $465,015
16,824 Added 44.76%
54,407 $1.02 Million
Q1 2022

May 16, 2022

SELL
$17.15 - $28.31 $672,948 - $1.11 Million
-39,239 Reduced 51.08%
37,583 $825,000
Q4 2021

Feb 14, 2022

BUY
$19.35 - $28.41 $206,251 - $302,822
10,659 Added 16.11%
76,822 $2.18 Million
Q3 2021

Nov 15, 2021

BUY
$16.88 - $25.23 $4,017 - $6,004
238 Added 0.36%
66,163 $1.39 Million
Q2 2021

Aug 16, 2021

BUY
$15.9 - $21.15 $271,254 - $360,819
17,060 Added 34.91%
65,925 $1.24 Million
Q1 2021

May 17, 2021

SELL
$13.3 - $17.55 $426,092 - $562,249
-32,037 Reduced 39.6%
48,865 $747,000
Q4 2020

Feb 16, 2021

BUY
$12.08 - $17.46 $977,296 - $1.41 Million
80,902 New
80,902 $1.14 Million

Others Institutions Holding CRNX

About Crinetics Pharmaceuticals, Inc.


  • Ticker CRNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,752,800
  • Market Cap $2.9B
  • Description
  • Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...
More about CRNX
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.